BSX - Boston Scientific Corporation

NYSE - Nasdaq Real Time Price. Currency in USD
36.70
-0.29 (-0.78%)
As of 11:42AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close36.99
Open37.14
Bid36.70 x 900
Ask36.71 x 800
Day's Range36.35 - 37.04
52 Week Range24.54 - 39.44
Volume1,610,561
Avg. Volume6,773,851
Market Cap50.753B
Beta (3Y Monthly)1.00
PE Ratio (TTM)96.83
EPS (TTM)0.38
Earnings DateOct 24, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.50
Trade prices are not sourced from all markets
  • Six blue-chip stocks to buy on the dip
    MarketWatch3 hours ago

    Six blue-chip stocks to buy on the dip

    When the stock market dips, prudent investors make a shopping list of stocks to buy. • The chart shows the support zone. • Regarding long-term thinking, it is better to think in terms of a support zone and support levels within that zone.

  • What Analysts Recommend for Medtronic
    Market Realist3 hours ago

    What Analysts Recommend for Medtronic

    How Is Medtronic Positioned in October? On October 12, Medtronic stock closed at $94.69, which is a ~1.7% rise from its prior-day close of $93.11 on October 11 and a ~24% rise from its 52-week low of $76.41. Medtronic hit its 52-week high of $100.15 on September 26, 2018.

  • InvestorPlace5 hours ago

    5 Blue Chip Stocks to Watch

    One of the most overlooked $54 billion companies in the market is  medical devices maker Boston Scientific, which is enjoying a great year. Most of the airline sector is boasting attractive valuations right now, and UAL stands out as it has shown great relative strength versus its peers this year.

  • Investor's Business Daily17 hours ago

    Dow Jones Futures: It's A Stock Market Correction; Here's What To Do

    Dow Jones futures: In a stock market correction, it's a good time to build a watch list. Check out Apple, UnitedHealth, Microsoft and other top stocks with strong relative strength.

  • Edwards Lifesciences’ Q3 2018 Earnings Estimates
    Market Realist3 days ago

    Edwards Lifesciences’ Q3 2018 Earnings Estimates

    Edwards Lifesciences (EW) will release its third-quarter earnings results on October 23. The company is expected to register adjusted EPS of ~$1.02, a ~21% YoY (year-over-year) rise. 

  • What to Expect of Edwards Lifesciences’ Q3 2018 Sales
    Market Realist3 days ago

    What to Expect of Edwards Lifesciences’ Q3 2018 Sales

    Edwards Lifesciences (EW) is scheduled to announce its third-quarter earnings results after the market closes on October 23. The company is a leading player in the artificial heart valve market.

  • Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results
    Market Realist3 days ago

    Analysts Raise Their Targets on EW ahead of Its Q3 2018 Results

    Edwards Lifesciences (EW) is a leading transcatheter heart valve manufacturer in the United States. The company is set to release its third-quarter earnings results after the market closes on October 23. In this article, we’ll look at analysts’ recommendations and target prices for EW ahead of its third-quarter earnings release. According to an October 12 Reuters survey, which included 21 analysts covering EW stock, 62% of analysts (or 13) have recommended “buys” or “strong buys” on Edwards Lifesciences.

  • A Look at Abbott Laboratories’ Third-Quarter Earnings Estimates
    Market Realist3 days ago

    A Look at Abbott Laboratories’ Third-Quarter Earnings Estimates

    On October 17, before the market opens, Abbott Laboratories plans to announce its earnings results for the third quarter of 2018. Wall Street expects Abbott to register Q3 adjusted EPS (earnings per share) of $0.74, which would be a YoY (year-over-year) increase of 12.9%. In the second quarter, it reported adjusted EPS of $0.73, up 17.7% YoY, which exceeded analysts’ estimates.

  • Abbott Laboratories Expected to Report Q3 Sales of $7.6 Billion
    Market Realist4 days ago

    Abbott Laboratories Expected to Report Q3 Sales of $7.6 Billion

    Abbott Laboratories (ABT) plans to release its earnings results for its third quarter of 2018 on October 17 before the market opens. Wall Street expects its sales to be $7.65 billion, up 12% YoY (year-over-year).

  • ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade
    Market Realist4 days ago

    ABT Stock Fell ~3.3% on October 10 despite Analyst Upgrade

    On October 10, Abbott Laboratories (ABT) ended the trading day at $68.92, down ~3.3% from the previous day’s close. On the day, Morgan Stanley raised its target price on ABT stock from $70 to $80. However, the stock price dropped as the broader market sell-off pulled down ABT stock prices along with a large number of other healthcare stocks. The SPDR S&P 500 ETF (SPY) was down ~3.2% on October 10.

  • Analysts Raise Target Prices on ABT ahead of Q3 Earnings
    Market Realist4 days ago

    Analysts Raise Target Prices on ABT ahead of Q3 Earnings

    Abbott Laboratories (ABT) is slated to announce its Q3 earnings results on October 17. Let’s look at Wall Street analysts’ recommendations for ABT stock ahead of its earnings release.

  • Here's Why You Should Invest in Boston Scientific Stock Now
    Zacks6 days ago

    Here's Why You Should Invest in Boston Scientific Stock Now

    Boston Scientific (BSX) is coming up with better-than-expected earnings and revenue performances on the back of growth across all business lines and geographies.

  • Boston Scientific Expects 6.4%–7.4% Sales Growth in Fiscal 2018
    Market Realist7 days ago

    Boston Scientific Expects 6.4%–7.4% Sales Growth in Fiscal 2018

    During the investor update at the TCT (Transcatheter Cardiovascular Therapeutics) meeting on September 24, Boston Scientific increased its long-term outlook. For 2019 and 2020, it now expects operational sales growth of 7%–10%, which compares to the previous guidance of 6%–9%. It expects growth to be driven by both organic and inorganic growth.

  • How Important Are Boston Scientific’s Valuation Multiples?
    Market Realist10 days ago

    How Important Are Boston Scientific’s Valuation Multiples?

    On October 4, Boston Scientific (BSX) was trading at a forward PE ratio of 24.7x compared to the industry average of 22.9x. Let’s look at another key valuation multiple, the EV-to-EBITDA ratio, which is a capital structure–neutral valuation metric. Boston Scientific’s forward EV-to-EBITDA multiple is 19.4x, which is higher than the industry average of 17.3x.

  • Analysts Still Bullish on Boston Scientific Stock in October
    Market Realist10 days ago

    Analysts Still Bullish on Boston Scientific Stock in October

    Boston Scientific (BSX) stock traded at its 52-week high on October 2. It has seen tremendous growth momentum over the past year on the back of strong product launches, approvals, and acquisitions.

  • What Triggered a 52-Week High for Boston Scientific in October?
    Market Realist10 days ago

    What Triggered a 52-Week High for Boston Scientific in October?

    Boston Scientific Has Massive Bull Run: Is There More Upside? On October 3, Boston Scientific (BSX) stock closed at $38.61, a decline of ~1.1% compared to $39.04 on October 2. It hit a 52-week high of $39.44 during the day on October 2 when Morgan Stanely raised its target price.

  • ABT Stock Registered a 52-Week High in October
    Market Realist10 days ago

    ABT Stock Registered a 52-Week High in October

    On October 4, Abbott Laboratories (ABT) ended the trading day at $71.82, down ~0.31% from the previous day’s close. The stock registered a 52-week high of $74.15 on October 1. Throughout the week, it’s fallen ~1.6%.

  • Why Boston Scientific (BSX) is Poised to Beat Earnings Estimates Again
    Zacks10 days ago

    Why Boston Scientific (BSX) is Poised to Beat Earnings Estimates Again

    Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

  • Analysts’ Recommendations on ABT Stock in October
    Market Realist10 days ago

    Analysts’ Recommendations on ABT Stock in October

    Abbott Laboratories (ABT) offers market-leading products and solutions across its Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals operating segments.

  • Barrons.com11 days ago

    Health-Care Stocks’ High Valuations May Not Be a Problem

    Wells Fargo notes that medtechs are at decade-high prices but are still below the robust 2000-2008 period.

  • Can You Still Profit From Boston Scientific’s Tremendous Run?
    InvestorPlace12 days ago

    Can You Still Profit From Boston Scientific’s Tremendous Run?

    Over the last six months, Boston Scientific (NYSE:BSX) has experienced an incredible rally. BSX stock has moved higher in 24 of the past 28 weeks, a streak that started back in March. As the weekly chart for BSX stock below shows the run and when it started.